Mackenzie Financial Corp Purchases 178 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mackenzie Financial Corp grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,728 shares of the medical research company’s stock after purchasing an additional 178 shares during the period. Mackenzie Financial Corp’s holdings in IQVIA were worth $9,655,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. AdvisorNet Financial Inc lifted its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $32,000. Activest Wealth Management bought a new stake in shares of IQVIA in the 4th quarter valued at about $35,000. CVA Family Office LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $43,000. Finally, Live Oak Investment Partners bought a new stake in shares of IQVIA in the 4th quarter valued at about $41,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.4 %

Shares of NYSE:IQV opened at $228.09 on Friday. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The firm has a market capitalization of $41.40 billion, a P/E ratio of 31.29, a P/E/G ratio of 2.20 and a beta of 1.50. The stock has a 50 day moving average price of $244.82 and a 200-day moving average price of $221.65. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same quarter in the prior year, the company earned $2.54 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IQV shares. UBS Group boosted their target price on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. SVB Leerink started coverage on IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Robert W. Baird increased their price objective on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Finally, Truist Financial increased their price objective on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.